Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-22

Study Completion Date

2021-02-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Replication of the RELY Anticoagulant Trial in Healthcare Claims Data

NCT04593043

Atrial Fibrillation

COMPLETED

Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data

NCT04736420

Venous Thromboembolism

COMPLETED

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

NCT04879407

Pulmonary Embolism

COMPLETED

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

NCT05083455

Deep Vein Thrombosis, Pulmonary Embolus

COMPLETED

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

NCT05264168

Venous Thromboembolism Pulmonary Embolism DVT

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates through standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Warfarin

Reference group

Warfarin

Intervention Type DRUG

Warfarin dispensing claim is used as the reference group

Dabigatran

Exposure group

Dabigatran

Intervention Type DRUG

Dabigatran dispensing claim is used as the exposure group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dabigatran

Dabigatran dispensing claim is used as the exposure group

Intervention Type DRUG

Warfarin

Warfarin dispensing claim is used as the reference group

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Market availability of dabigatran in the U.S. for treatment of deep vein thrombosis and pulmonary embolism started on April 7, 2014

* For Medicare: April 7, 2014 - December 31, 2017 (end of available data)
* For Marketscan: April 7, 2014 - December 31, 2018 (end of available data)
* For Optum: April 7, 2014 - March 31, 2020 (end of available data)

* Acute deep vein thrombosis (DVT) of the leg involving proximal veins, and/or pulmonary embolism (PE) iin patients for whom at least 6 months of anticoagulant therapy is considered appropriate.
* Men and women ages 18 years or greater

Exclusion Criteria

* PE satisfying at least one of the following criteria:

* Haemodynamic instability
* OR Embolectomy is indicated or performed
* OR thrombolytic therapy is indicated or performed
* OR suspected source of PE is other than blood clots from the legs
* Actual or anticipated use of vena cava filter
* Patients who in the investigators judgement are perceived as having an excessive risk of bleeding
* Known anaemia
* Need of anticoagulant treatment for disorders other than VTE
* Recent unstable cardiovascular disease
* Elevated AST or ALT \> 3x ULN
* Liver disease expected to have any potential impact on survival (severe liver conditions)
* Severe renal impairment
* Contraindications to anticoagulant therapy (not specified)
* Recent or active major bleeding
* Recent brain, eye, or spinal cord injury or surgery
* Malignant or severe, uncontrolled hypertension
* Active infective endocarditis
* Mechanical prosthetic heart valve (recently implanted - RE-ALIGN trial)
* Women who are pregnant, nursing, or of childbearing potential who refuse to use a medically acceptable form of contraception
* Patients who have developed transaminase elevations upon exposure to ximelagatran
* Patients considered unsuitable for inclusion by the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No